Tip	Description	Benefit
Use a stable internet connection	To prevent data loss during submission	Faster processing
Prepare necessary documents	ID and medical history if required	Smooth verification process
Double-check entries	Ensure accuracy before submitting	Reduces need for follow-up
Read instructions carefully	To avoid missing important information	Completes the process efficiently

Patients who reported that they or an immediate family member were currently employed with Pfizer, Upjohn, United BioSource (UBC, the survey vendor) or the UK Medicines and Healthcare products Regulatory Agency (MHRA) were excluded from the study. The survey included questions/statements that inquired about the patient’s experience at the point of VC supply in the pharmacy, including whether they were: Assessed for suitability for VC (eg, for cardiovascular and other health conditions), Advised by a pharmacist to consult their doctor within 6 months of first supply, Visited their doctor or planned to visit their doctor very soon, Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about potential causes of ED and offered lifestyle advice. Screening questions (ie, consent, gender, patient, or family member employed by Pfizer, Upjohn, UBC or UK MHRA, purchase of VC and for whom). Pharmacy and pharmacist characteristics (ie, urban vs rural and chain vs independent pharmacy; gender of the pharmacist). Patient characteristics (ie, age, confirmation of ED symptoms, history of prescribed ED medications). Patient’s experience when requesting VC for the first time (ie, when was the first purchase of VC, the types of questions that the pharmacist asked a patient, type of counselling received from the pharmacist, whether the patients were advised to contact their doctor, receipt of a patient record tear-off slip from a pharmacist, how comfortable the patient was with counselling from the pharmacist). Patient’s experience with or intention to see, a doctor (ie, has a patient seen a doctor, or intends to consult a doctor in the near future). Source of patient’s knowledge about VC. A structured and self-administered questionnaire comprising of close-ended questions or statements with multiple response choices was used to collect the survey data. The survey was designed to be completed voluntarily and was programmed to encrypt all identifiable information and respondent identifiers, which were stored separately within the database.

Avarante 10mg - 2 Tablets

The participants’ experience of whether they were assessed for suitability for VC use by their pharmacist the first time they asked for VC is shown (Table 2). About 35.4% (n=105) of the participants reported being advised to consult their doctor within 6 months of their first supply of VC. Likewise, 11.1% (n = 33) of them reported that they were advised to see their doctor within one month of the first supply, 2.4% (n = 7) of them were advised to see their doctor immediately, and another 2.4% (n = 7) of them were advised to see their doctor within a year of the first supply. About 16.5% (n = 49) of them reported that they were not advised by their pharmacist to see their doctor and 32.3% (n = 96) of them could not recall if they were advised. Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (Table 3).

Supplementary Information

In addition, of the 297 participants, 39.1% (n = 116) reported receiving the tear-off slip with a reminder of when to see their doctor, 23.2% (n = 69) could not remember, and 37.7% (n = 112) stated that they did not receive any tear-off slip. Approximately two-thirds of participants (65.0%; n = 193) reported that they either had seen (19.2%; n = 57) or planned to see (45.8%; n = 136) their doctor. Of the 19.2% (n = 57) participants who reported having seen their doctors, majority of them (16.8%; n = 50 [12.8–21.6]) were told by their doctors that they could continue with VC by buying it at the pharmacy without a prescription, while rest of them (n = 7) were not advised to do so. Among the remaining 35% (n = 104) of the participants, 28.3% (n = 84) of them reported not having seen their doctor and had no plans to discuss VC with their doctor. Patients’ experience with visiting or planning to visit their doctor in the near future are shown (Table 4). Personal identifiable information of the participants was stored separately and only were used for processing the respondents’ honorarium, where applicable. Each participant was randomly assigned a unique code to access the survey. This code was deactivated upon its use to prevent the code from being used repeatedly and complete the survey multiple times. Once the participant started the survey, it had to be completed and there was no opportunity to return to the survey later. The participant was permanently logged out of the survey following 30 minutes of inactivity. Once the survey was completed, it was not possible to link the survey to an individual. The participants did not have to actively decline to complete the survey. Therefore, the study operator had no ability to track which participants actively decided to not complete the survey. This survey design encouraged participation and answering honestly by ensuring that the responses were completely anonymous.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	25mg	90 + 6 Pills	105.03€ 100.03€
Viagra Professional	100mg	270 + 6 Pills	456.97€ 435.21€
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€
Viagra Generic	50mg	90 + 6 Pills	107.37€ 102.26€
Viagra Super Active	100mg	360 + 30 Pills	470.93€ 448.50€
Viagra Original	100mg	8 Pills	59.84€ 56.99€
Viagra Generic	25mg	30 + 4 Pills	47.97€ 45.69€
Viagra Generic	150mg	180 + 10 Pills	236.46€ 225.20€
Viagra Original	100mg	76 + 4 Pills	306.59€ 291.99€
Viagra Generic	200mg	90 + 6 Pills	170.79€ 162.66€
Viagra Generic	25mg	120 + 6 Pills	125.56€ 119.58€

Hot Offers

Male patients who were willing and consented to participate in this self-administered survey and reported that they purchased at least one supply of VC from the pharmacist for their own use were included in the study. Patients who reported that they or an immediate family member were currently employed with Pfizer, Upjohn, United BioSource (UBC, the survey vendor) or the UK Medicines and Healthcare products Regulatory Agency (MHRA) were excluded from the study. The survey included questions/statements that inquired about the patient’s experience at the point of VC supply in the pharmacy, including whether they were: Assessed for suitability for VC (eg, for cardiovascular and other health conditions), Advised by a pharmacist to consult their doctor within 6 months of first supply, Visited their doctor or planned to visit their doctor very soon, Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about potential causes of ED and offered lifestyle advice. Screening questions (ie, consent, gender, patient, or family member employed by Pfizer, Upjohn, UBC or UK MHRA, purchase of VC and for whom). Pharmacy and pharmacist characteristics (ie, urban vs rural and chain vs independent pharmacy; gender of the pharmacist).

Participation inViagra Connect®training guide to pharmacists

Patient characteristics (ie, age, confirmation of ED symptoms, history of prescribed ED medications). Patient’s experience when requesting VC for the first time (ie, when was the first purchase of VC, the types of questions that the pharmacist asked a patient, type of counselling received from the pharmacist, whether the patients were advised to contact their doctor, receipt of a patient record tear-off slip from a pharmacist, how comfortable the patient was with counselling from the pharmacist). Patient’s experience with or intention to see, a doctor (ie, has a patient seen a doctor, or intends to consult a doctor in the near future). Source of patient’s knowledge about VC. A structured and self-administered questionnaire comprising of close-ended questions or statements with multiple response choices was used to collect the survey data.

Patients’ Experience with Visiting or Planning to Visit Their Doctor

The survey was designed to be completed voluntarily and was programmed to encrypt all identifiable information and respondent identifiers, which were stored separately within the database. Personal identifiable information of the participants was stored separately and only were used for processing the respondents’ honorarium, where applicable. Each participant was randomly assigned a unique code to access the survey. This code was deactivated upon its use to prevent the code from being used repeatedly and complete the survey multiple times. Once the participant started the survey, it had to be completed and there was no opportunity to return to the survey later. In this study, the aim was to obtain at least 300 completed surveys, which considers statistical and practical considerations of participation in this type of surveys.

Avarante 10mg - 4 Tablets

A total of 5144 pharmacies, covering a wide geography of UK, were invited to participate in this study. This included 1552 (30%) of Boots Pharmacies, 2040 (40%) of independent pharmacies and 1552 (30%) of regional multiple pharmacies. Of these, 430 pharmacies agreed viagra tablet for sex to participate in the study. For enrollment of Participants in the survey, 33,690 patient survey invitation leaflets were sent to 130 registered pharmacies between 18 September 2020 and 08 October 2020 in wave one (ie, 1st batch of mailing) and 58,258 invitation leaflets were sent to 300 registered pharmacies between 17 May 2020 and 15 June 2021 in wave two (ie, 2nd batch of mailing). Wave two mailing was added because the number of participants did not reach the 300 targets in wave one.

What is the difference between Prescription Viagra and Viagra Connect?

A total of 412 patients were screened for eligibility, of which 73.5% (n = 303) of them met the inclusion criteria. About 98.0% (n = 297/303) of the study participants completed the survey while 2.0% of them (n = 6) initiated the survey but did not complete it. The average time to complete this web-based survey was 4.2 minutes, with 72.1% (n = 214) of the participants completed the survey in less than 5 minutes. Patient demographics showed that 45.5% (n = 135) and 41.4% (n = 123) of the participants were in the age group of 41–60 years and 18–40 years, respectively. Symptoms of ED was reported by 86.2% (n = 256) of the participants, 13.8% (n = 41) reported that they were prescribed sildenafil or other ED medication by their doctor and 28.3% (n = 84) reported first purchase of VC from their pharmacist within the last month.

Assessment by Pharmacist for Patient Suitability for VC

Most of the participants reported that the pharmacy they purchased VC for the first time was in an urban area (75.4%; n = 224), was an independent pharmacy (56.2%; n = 167), and the pharmacist was male (61.3%; n = 182). Further details on patient demographics, pharmacy and patient characteristics are shown (Table 1). Participants reported that their pharmacist asked questions about their blood pressure (BP) and heart conditions (91.9%; n = 273), any other illnesses (87.9%; n = 261), or concomitant medications usage (86.5%; n = 257). About 82.2% (n = 244) of the participants reported being asked if they had ED, and 71.7% (n = 213) reported of being asked whether their doctor had advised them about their physical/sexual fitness. Overall, 61.3% (n = 182) of the participants reported being assessed for suitability for VC on all 5 items. With a sample size of 300, the statistical precision around the estimate will be ±5.8%. The precision of the estimate calculations is based on the assumption that 50% of the participating patients report that they were assessed by a pharmacist for suitability for Viagra Connect and 50% report that they were advised by a pharmacist to consult their doctor. Basing the sample size estimate on this assumption that 50% patients reporting the desired outcome related to the primary objectives is the most conservative approach, since either a higher or lower percentage than 50% will lead to higher statistical precision. Data collected from the survey were summarized with descriptive statistics and no statistical comparisons were made using hypothesis testing. Patient responses were considered for frequency distributions with 95% confidence intervals (CIs) and survey data were stratified based on pharmacy and patient characteristics. Subgroup analyses for participants responses to the questions regarding pharmacists’ assessment of their suitability for VC, and advice on appropriate use of VC and on their need to see doctors were performed by the stratification of the following variables: • Age-group (18–40 years, 41–60 years, or 61 years or older); • Having symptoms of ED (Yes or No); • Having been prescribed sildenafil or other ED medication by the doctor (Yes or No); • Type of pharmacy (chain pharmacy, or independent pharmacy); • Survey completion status (completers, or non-completers); • Whether the pharmacists asked the patient if he has ED (Yes or No). A total of 5144 pharmacies, covering a wide geography of UK, were invited to participate in this study.

Viagra Connect requires a brief health assessment at purchase.
Patients should disclose any health issues or medications.
Alcohol consumption may reduce effectiveness.
It does not cause an instant erection; arousal needed.
Side effects are usually mild and temporary.
Seek medical advice if experiencing persistent problems.

This included 1552 (30%) of Boots Pharmacies, 2040 (40%) of independent pharmacies and 1552 (30%) of regional multiple pharmacies. Of these, 430 pharmacies agreed viagra tablet for sex to participate in the study.

How to take Priligy

The participant was permanently logged out of the survey following 30 minutes of inactivity. Once the survey was completed, it was not possible to link the survey to an individual. The participants did not have to actively decline to complete the survey. Therefore, the study operator had no ability to track which participants actively decided to not complete the survey. This survey design encouraged participation and answering honestly by ensuring that the responses were completely anonymous.

Who Can Use Viagra Connect?

Following a question to obtain the patient’s consent to participate, the survey included a screening module with questions to confirm eligibility. Depending on the answers to the screening questions, survey participation was either terminated or continued. If ineligible, the participant was immediately notified with a “thank you” message that survey participation has ended. In this study, the aim was to obtain at least 300 completed surveys, which considers statistical and practical considerations of participation in this type of surveys. With a sample size of 300, the statistical precision around the estimate will be ±5.8%.

Online survey

The precision of the estimate calculations is based on the assumption that 50% of the participating patients report that they were assessed by a pharmacist for suitability for Viagra Connect and 50% report that they were advised by a pharmacist to consult their doctor. Basing the sample size estimate on this assumption that 50% patients reporting the desired outcome related to the primary objectives is the most conservative approach, since either a higher or lower percentage than 50% will lead to higher statistical precision. Data collected from the survey were summarized with descriptive statistics and no statistical comparisons were made using hypothesis testing. Patient responses were considered for frequency distributions with 95% confidence intervals (CIs) and survey data were stratified based on pharmacy and patient characteristics. Subgroup analyses for participants responses to the questions regarding pharmacists’ assessment of their suitability for VC, and advice on appropriate use of VC and on their need to see doctors were performed by the stratification of the following variables: • Age-group (18–40 years, 41–60 years, or 61 years or older); • Having symptoms of ED (Yes or No); • Having been prescribed sildenafil or other ED medication by the doctor (Yes or No); • Type of pharmacy (chain pharmacy, or independent pharmacy); • Survey completion status (completers, or non-completers); • Whether the pharmacists asked the patient if he has ED (Yes or No). For enrollment of Participants in the survey, 33,690 patient survey invitation leaflets were sent to 130 registered pharmacies between 18 September 2020 and 08 October 2020 in wave one (ie, 1st batch of mailing) and 58,258 invitation leaflets were sent to 300 registered pharmacies between 17 May 2020 and 15 June 2021 in wave two (ie, 2nd batch of mailing). Wave two mailing was added because the number of participants did not reach the 300 targets in wave one. A total of 412 patients were screened for eligibility, of which 73.5% (n = 303) of them met the inclusion criteria. About 98.0% (n = 297/303) of the study participants completed the survey while 2.0% of them (n = 6) initiated the survey but did not complete it. The average time to complete this web-based survey was 4.2 minutes, with 72.1% (n = 214) of the participants completed the survey in less than 5 minutes. Patient demographics showed that 45.5% (n = 135) and 41.4% (n = 123) of the participants were in the age group of 41–60 years and 18–40 years, respectively. Symptoms of ED was reported by 86.2% (n = 256) of the participants, 13.8% (n = 41) reported that they were prescribed sildenafil or other ED medication by their doctor and 28.3% (n = 84) reported first purchase of VC from their pharmacist within the last month. Most of the participants reported that the pharmacy they purchased VC for the first time was in an urban area (75.4%; n = 224), was an independent pharmacy (56.2%; n = 167), and the pharmacist was male (61.3%; n = 182).

Product details

Regarding the other additional advice, the participants received from the pharmacists, 85.5% (; n = 254) reported being advised on how to take VC correctly, 82.2% (n = 244) reported that they were advised of possible side effects, for which they might have to discontinue taking VC and consult their doctor. Further details on patient demographics, pharmacy and patient characteristics are shown (Table 1). Participants reported that their pharmacist asked questions about their blood pressure (BP) and heart conditions (91.9%; n = 273), any other illnesses (87.9%; n = 261), or concomitant medications usage (86.5%; n = 257). About 82.2% (n = 244) of the participants reported being asked if they had ED, and 71.7% (n = 213) reported of being asked whether their doctor had advised them about their physical/sexual fitness. Overall, 61.3% (n = 182) of the participants reported being assessed for suitability for VC on all 5 items.

Education on safe use is essential for users.
Proper storage ensures medication potency.
Keep out of reach of children.
Be aware of possible drug interactions.
Medication should be used only under guidance.
Regular consultation can prevent complications.

What is Eroxon Gel

About 16.5% (n = 49) of them reported that they were not advised by their pharmacist to see their doctor and 32.3% (n = 96) of them could not recall if they were advised. Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (Table 3). In addition, of the 297 participants, 39.1% (n = 116) reported receiving the tear-off slip with a reminder of when to see their doctor, 23.2% (n = 69) could not remember, and 37.7% (n = 112) stated that they did not receive any tear-off slip. Approximately two-thirds of participants (65.0%; n = 193) reported that they either had seen (19.2%; n = 57) or planned to see (45.8%; n = 136) their doctor.

Viagra Connect offers a discreet way to manage ED.
It works best when taken on an empty stomach.
Full effect may take up to an hour to manifest.
Avoid heavy meals immediately before taking.
Regular use does not lead to dependency.
An active lifestyle may improve results.

Of the 19.2% (n = 57) participants who reported having seen their doctors, majority of them (16.8%; n = 50 [12.8–21.6]) were told by their doctors that they could continue with VC by buying it at the pharmacy without a prescription, while rest of them (n = 7) were not advised to do so.

The packaging includes clear dosing instructions.
Pharmacists can advise on proper usage and precautions.
Do not share medication with others.
Discontinue use if side effects worsen.
Report any adverse reactions to a healthcare provider.
Keep track of your dosage schedule for safety.

Among the remaining 35% (n = 104) of the participants, 28.3% (n = 84) of them reported not having seen their doctor and had no plans to discuss VC with their doctor. Patients’ experience with visiting or planning to visit their doctor in the near future are shown (Table 4). Regarding the other additional advice, the participants received from the pharmacists, 85.5% (; n = 254) reported being advised on how to take VC correctly, 82.2% (n = 244) reported that they were advised of possible side effects, for which they might have to discontinue taking VC and consult their doctor.

Completing the Health Declaration for Viagra Connect